Report Summary
The Healthcare Partnering and M&A Yearbook 2012 report provides comprehensive understanding and unprecedented access to the partnering and M&A deals and agreements entered into by the worlds leading healthcare companies during 2011.
- Bigpharma partnering activity during 2011
- Top partnering deals by value in 2011
- Top M&A deals by value in 2011
- Most active dealmakers 2011
- Comprehensive coverage of every deal announced in 2011
Description
The Partnering and M&A Yearbook 2012 report provides comprehensive understanding and unprecedented access to the partnering and M&A deals and agreements entered into by the worlds leading healthcare companies during 2011.
Using this report, dealmakers will effectively and efficiently gain insight into the partnering activities of the past year. The report allows you to view all the partnering, alliances and M&A deals announced worldwide.
Chapter 1 provides an introduction to the report, whilst chapters 2 and 3 provide an overview of partnering and M&A trends, respectively, in 2011. The key partnering and M&A deals of 2011 are reviewed, as well as forecasts for dealmaking in 2012.
Chapter 4 analyzes the most active dealmakers in partnering and M&A during 2011.
Chapter 5 provides an overview of the leading deals for 2011 by headline value. The chapter provides covers both partnering and M&A dealmaking during the year.
The main body of the report is provided in chapters 6, 7 and 8.
Chapter 6 provides an in-depth review of every bigpharma company provides the reader with a breakdown of that company’s dealmaking during 2011 by deal type, stage of development and therapy focus. Each company entry is supplemented with a comprehensive listing of deals entered into during 2011, complete with a hyperlink to the deal record online. Where a contract document is available, this may also be found in the deal record online as filed with the SEC.
Chapter 7 provides a comprehensive directory of partnering activity during 2011. The deals are listed by company A-Z, industry sector, deal type, stage of development and therapy focus, allowing easy access to deals and alliances of interest. Every deal record links to an online, live version of the deal record at the Current Agreements deals and alliances database. Where available, deal records also include the contract document as disclosed at the SEC.
Chapter 8 provides a comprehensive directory of partnering and M&A activity during 2011. The deals are listed by company A-Z, and industry sector, allowing easy access to deals and alliances of interest. Every deal record links to an online, live version of the deal record at the Current Agreements deals and alliances database. Where available, deal records also include the contract document as disclosed at the SEC.
One of the key aspects of partnering is conducting due diligence on a partner to determine under what terms a prospective partner agrees to a partnering relationship.
Understanding the flexibility of prospective partners’ negiotated deals terms provides critical insight into the negotiation process in termsof what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases and databases do not.
In addition, contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each parties ability to derive value from the deal.
In summary, the report provides the reader with the resources necessary to make research and understand the partnerships, alliances and M&A deals of 2011.
Benefits
Partnering and M&A Yearbook 2012 provides the reader with the following key benefits:
- In-depth understanding of dealmaking trends in 2011
- Comprehensive access to over 3,500 partnering and 600 M&A deals entered into by the world’s biopharma companies during 2011
- Detailed access to actual partnership and M&A deals and contracts entered into by the leading fifty bigpharma companies
- Understand the key deal terms companies have agreed in previous deals
- Undertake due diligence to assess suitability of your proposed deal terms for partner companies
Scope
Partnering and M&A Yearbook 2012 is intended to provide the reader with an in-depth understanding and access to parthering and M&A trends and structure of deals entered into by leading companies worldwide.
Partnering and M&A Yearbook 2012 includes:
- Trends in dealmaking in the biopharma industry
- Analysis of partnering and M&A deal structure
- Comprehensive directory of partnering and M&A deals in 2011
- Links to online access to over 3,500 partnering and 600 M&A deals
- The leading partnering and M&A deals by value in 2011
- Most active partnering and M&A dealmakers during 2011
In Partnering and M&A Yearbook 2012, the partnering and M&A deals are listed by:
- Company A-Z
- Headline value
- Stage of development at signing
- Deal component type
- Specific therapy target
- Technology type
Each deal title links via Weblink to an online version of the deal record at Current Agreements and where available, the contract document, providing easy access to each contract document on demand.